GlassScriptPhysician profile
Adrianna Mills
NPI 1962022798
$8,680.96
in general payments reported to CMS, 2019-2025
29 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $344 · 2022: $2,299 · 2023: $1,600 · 2024: $2,552 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,558 · Education: $480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,558.21 |
| Education | $479.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,652.86 | 2022-2025 | |
| Janssen Biotech, INC. | $1,588.93 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $648.08 | 2021-2025 | Dupixent |
| Genzyme Corporation | $546.00 | 2022-2025 | |
| Amgen INC. | $443.89 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $425.27 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $417.83 | 2023-2025 | Sotyktu |
| Incyte Corporation | $339.93 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $319.96 | 2022-2025 | |
| Lilly USA, LLC | $300.32 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $249.53 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $225.14 | 2022 | |
| Sun Pharmaceutical Industries INC. | $223.96 | 2021-2025 | |
| Leo Pharma INC. | $215.72 | 2022-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $210.97 | 2021-2025 | Cabtreo, Jublia, Arazlo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $186.32 | 2023-2024 | Vtama |
| Journey Medical Corporation | $127.84 | 2022 | |
| Pfizer INC. | $116.09 | 2022 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Arcutis Biotherapeutics, INC. | $86.46 | 2023-2025 | Zoryve |
| Almirall LLC | $46.66 | 2022-2023 | Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.91 | 2023 | Spevigo |
| Allergan, INC. | $37.60 | 2022 | |
| Mayne Pharma Commercial LLC | $32.74 | 2022-2023 | |
| Iovance Biotherapeutics, INC. | $26.68 | 2025 | Amtagvi |
| Biofrontera INC. | $22.08 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Verrica Pharmaceuticals INC. | $18.29 | 2025 | Ycanth |
| Organon LLC | $17.72 | 2025 | |
| Genentech USA, INC. | $13.19 | 2023 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrianna Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.